Figure 3
From: Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
Kaplan–Meier analysis of progression-free survival (PFS) and overall survival (OS). PFS is shown in A and C. OS is shown in B and D. PFS and OS were examined based on rilotumumab dose in the MET-positive (A, B) and MET-negative subgroups (C, D). MET positivity was defined as ⩾25% membranous staining of tumour cells at any intensity, and MET negativity was defined as <25% membranous staining. CI, confidence interval.
